Erectile dysfunction (ED) is a common sexual dysfunction in men and is defined as the inability to attain or maintain an adequate penile erection during sexual intercourse, impeding the achievement of a satisfactory sexual activity (
1). Disruption of any component of the erection response, such as organic, relational, and psychological factors, can cause ED (
2). A wide range of external signals, including visual, auditory, and olfactory signals, as well as penile local stimuli, can disrupt the erection response through a complicated physiological cascade involving neurologic, vascular, and humoral processes (
3). The erection process is triggered by the activation of the parasympathetic system, which leads to decreased levels of intracellular calcium, the relaxation of cavernosal smooth muscles, and increased blood flow (
4). According to an epidemiological study, the prevalence of ED in all age groups in southern Europe and English-speaking countries was reported to be 12.9% and 20.6%, respectively (
5). An updated retrospective cross-sectional study assessed the prevalence of ED in eight countries that had a great burden of the disease, reporting an overall prevalence of ED varying from 37% in Brazil to 49% in Italy (
5). Erectile dysfunction has detrimental impacts on patients’ quality of life and self-esteem. Moreover, it can cause deleterious psychological symptoms such as depression and anxiety in patients, and these effects can also affect their sexual partners (
1,
2). As ED results from a complicated interaction between psychological and physiological processes, American Urological Association (AUA) guidelines recommend mental health counseling as an adjunctive treatment for affected individuals (
6). Erectile dysfunction has been reported to be associated with endothelial dysfunction, such as impaired nitric oxide/cyclic guanosine 3′5′-monophosphate (NO-cGMP) signaling pathway. Thus, ED can be an early manifestation and predictor of generalized endothelial dysfunction and related abnormalities, as well as other forms of cardiovascular diseases (
7). The risk factors of ED include age, depression, obesity, cardiovascular disease, hypertension, diabetes mellitus, and spinal cord injury, as well as psychological factors (
7,
8).
Therapeutic options for ED vary from non-invasive to invasive therapy and include lifestyle modification, oral drugs, intracavernosal injections (ICIs), vacuum-assisted erectile devices (VED), and penile prostheses, as well as novel treatments, such as stem cell therapy, shockwave therapy, and the use of platelet-rich plasma (
9). Common oral medications are sildenafil, tadalafil, vardenafil, and avanafil, which act as an inhibitor of phosphodiesterase type 5 (PDE5) (
9). Oral medications are the first line of therapy in patients with refractory to lifestyle changes; approximately 60 - 65% of men diagnosed with ED, and those with other comorbidities such as hypertension, diabetes mellitus, and spinal cord injury, show successful treatment to complete intercourse of PDE5 inhibitors (
10-
13).
We found no well-designed study on the effect of spinal anesthesia on erectile function in patients undergoing surgeries, particularly urologic endoscopic surgeries and other types of procedures that need spinal anesthesia. In addition to the association between spinal anesthesia and erectile function, studies have shown that spinal anesthesia leads to changes in penile length during and after surgery. A growing body of evidence has demonstrated that spinal anesthesia can lead to priapism, which is defined as the prolonged erection of the penis without any sexual arousal/desire. Priapism is a relatively rare phenomenon that may occur as a result of an imbalance between the sympathetic and parasympathetic nervous systems. This phenomenon can bring significant troubles, such as excessive bleeding, for surgeons and other medical teams during surgeries (
14,
15).